Medarex Receives Milestone Payment From ImClone
News Jan 31, 2006
Medarex, Inc. has announced that it received a milestone payment from its licensing partner, ImClone Systems Incorporated, following the acceptance of an Investigational New Drug (IND) application for a fully human IgG1 antibody for the treatment of cancer.
The antibody was developed using Medarex's UltiMAb® technology. Medarex may receive future milestone payments and royalties should this product candidate progress through clinical development and to the market.
"We believe that the advancement of the ImClone Systems' antibody into clinical trials further demonstrates the strength of Medarex's UltiMAb technology," said Donald L. Drakeman, President and CEO of Medarex.
"With the broadening use of our UltiMAb platform, we expect to see a continual movement of new product candidates into clinical trials that goes beyond the thirty candidates currently in clinical development by us and our partners."
Restoring the ability to walk following spinal cord injury requires neurons in the brain to reestablish communication pathways with neurons in the spinal cord, Mature neurons, however, are unable to regenerate their axons to facilitate this process. New research in mice shows one potential route to overcome this limitation may be by targeting liver kinase B1 (LKB1) protein.
With machine learning systems now being used to determine everything from stock prices to medical diagnoses, it's never been more important to look at how they arrive at decisions. A new approach out of MIT demonstrates that the main culprit is not just the algorithms themselves, but how the data itself is collected.
International Conference on Cell and Structural biology
Jul 15 - Jul 16, 2019